Related Experiment Videos
Expression of endothelin in equine laminitis
L C Katwa1, P J Johnson, V K Ganjam
1Department of Internal Medicine, School of Medicine, University of Missouri, Columbia 65211, USA.
Equine Veterinary Journal
|July 13, 1999
Summary
Endothelin-1 (ET-1) levels are significantly higher in the hoof tissues of laminitic horses compared to healthy horses. This finding suggests ET-1 plays a key role in equine laminitis pathophysiology.
Area of Science:
- Veterinary Medicine
- Equine Health
- Biochemistry
Background:
- Endothelin-1 (ET-1) is a potent vasoconstrictor whose biosynthesis increases after myocardial infarction in humans.
- Pathological changes in equine laminitis share similarities with myocardial connective tissue changes post-myocardial infarction.
- Investigating ET-1 in equine laminitis may reveal new insights into the condition's development.
Purpose of the Study:
- To determine if ET-1 expression is elevated in the connective tissues of equine hooves affected by laminitis.
- To compare ET-1 levels in laminitic horses with those in healthy control horses.
Main Methods:
- Tissue samples were collected from three groups of horses: experimentally induced acute laminitis, chronic laminitis, and healthy controls.
- Endothelin-1 (ET-1) concentration was measured in the laminar connective tissues of all horses.
- Statistical analysis was performed to compare ET-1 levels between groups.
Main Results:
- Concentrations of ET-1 were significantly increased in the laminar connective tissues of all laminitic horses compared to controls.
- Both experimentally induced acute and spontaneously occurring chronic laminitic horses showed elevated ET-1 levels.
- Chronic laminitic horses exhibited higher ET-1 concentrations than those with acute laminitis.
Conclusions:
- Increased ET-1 expression in equine hoof connective tissues is strongly implicated in the pathophysiology of laminitis.
- ET-1 may represent a significant, previously unrecognized factor in equine laminitis.
- Future research should explore ET-1 converting enzyme inhibitors and receptor antagonists for laminitis treatment and prevention.